Novel Homozygous Pathogenic Variant in DNAJC6 Causes Rapid Progressive Parkinsonism.
The novel DNAJC6 p.Cys325* variant is associated with severe, early-onset parkinsonism and developmental regression and should be considered in children and adolescents presenting with parkinsonism plus neurodevelopmental decline, particularly when levodopa benefit is modest, and dose-related adverse motor crises occur.